Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology

European Journal of Cancer

Volumn 71, Issue , 2017, Pages 25-33

  Lambertini, Matteo ^a,b   Cinquini, Michela ^c   Moschetti, Ivan ^c   Peccatori, Fedro A ^d   Anserini, Paola ^a   Valenzano Menada, Mario ^a   Tomirotti, Maurizio ^e   Del Mastro, Lucia ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Breast cancer; Fertility preservation; Grades of Recommendation, Assessment, Development, and Evaluation (GRADE); Italian Association of Medical Oncology (AIOM); Luteinising hormone releasing hormone analogues (LHRHa); Premature ovarian failure

Indexed keywords

ANTINEOPLASTIC AGENT; GONADORELIN DERIVATIVE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GONADORELIN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL PRACTICE; DECISION MAKING; DRUG EFFICACY; FEMALE; FEMALE FERTILITY; FERTILITY PRESERVATION; HUMAN; MEDICAL ONCOLOGIST; OVARIAN PRESERVATION; OVARY FUNCTION; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; DRUG EFFECTS; FERTILITY; PRIMARY OVARIAN INSUFFICIENCY; PROCEDURES;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FERTILITY; FERTILITY PRESERVATION; GONADOTROPIN-RELEASING HORMONE; HUMANS; PRIMARY OVARIAN INSUFFICIENCY;

EID: 85003864905     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.10.034     Document Type: Review

References (30)

1. [1] Poggio, F., Levaggi, A., Lambertini, M., Chemotherapy-induced premature ovarian failure and its prevention in premenopausal breast cancer patients. Expert Rev Quality Life Cancer Care 1:1 (2016), 5–7.
2. [2] Ruddy, K.J., Partridge, A.H., Fertility (male and female) and menopause. J Clin Oncol 30:30 (2012), 3705–3711.
3. [3] Ruddy, K.J., Gelber, S.I., Tamimi, R.M., Ginsburg, E.S., Schapira, L., Come, S.E., et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol 32:11 (2014), 1151–1156.
4. [4] Loren, A.W., Mangu, P.B., Beck, L.N., Brennan, L., Magdalinski, A.J., Partridge, A.H., et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31:19 (2013), 2500–2510.
5. [5] Peccatori, F.A., Azim, H.A. Jr., Orecchia, R., Hoekstra, H.J., Pavlidis, N., Kesic, V., et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24:Suppl. 6 (2013), vi160–vi170.
6. [6] Paluch-Shimon, S., Pagani, O., Partridge, A.H., Bar-Meir, E., Fallowfield, L., Fenlon, D., et al. Second international consensus guidelines for breast cancer in young women (BCY2). Breast 26 (2016), 87–99.
7. [7] Lambertini, M., Del Mastro, L., Pescio, M.C., Andersen, C.Y., Azim, H.A. Jr., Peccatori, F.A., et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med, 14(1), 2016, 1.
8. [8] Guyatt, G.H., Oxman, A.D., Schünemann, H.J., Tugwell, P., Knottnerus, A., GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 64:4 (2011), 380–382.
9. [9] Brouwers, M.C., Kerkvliet, K., Spithoff, K., AGREE Next Steps Consortium. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. BMJ, 352, 2016, i1152.
10. [10] Badawy, A., Elnashar, A., El-Ashry, M., Shahat, M., Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 91:3 (2009), 694–697.
11. [11] Sverrisdottir, A., Nystedt, M., Johansson, H., Fornander, T., Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 117:3 (2009), 561–567.
12. [12] Gerber, B., von Minckwitz, G., Stehle, H., Reimer, T., Felberbaum, R., Maass, N., et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 29:17 (2011), 2334–2341.
13. [13] Del Mastro, L., Boni, L., Michelotti, A., Gamucci, T., Olmeo, N., Gori, S., et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 306:3 (2011), 269–276.
14. [14] Munster, P.N., Moore, A.P., Ismail-Khan, R., Cox, C.E., Lacevic, M., Gross-King, M., et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 30:5 (2012), 533–538.
15. [15] Elgindy, E.A., El-Haieg, D.O., Khorshid, O.M., Ismail, E.I., Abdelgawad, M., Sallam, H.N., et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol 121:1 (2013), 78–86.
16. [16] Song, G., Gao, H., Yuan, Z., Effect of leuprolide acetate on ovarian function after cyclophosphamide-doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial. Med Oncol, 30(3), 2013, 667.
17. [17] Karimi-Zarchi, M., Forat-Yazdi, M., Vafaeenasab, M.R., Nakhaie-Moghadam, M., Miratashi-Yazdi, A., Teimoori, S., et al. Evaluation of the effect of GnRH agonist on menstrual reverse in breast cancer cases treated with cyclophosphamide. Eur J Gynaecol Oncol 35:1 (2014), 59–61.
18. [18] Moore, H.C.F., Unger, J.M., Phillips, K.-A., Boyle, F., Hitre, E., Porter, D., et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372:10 (2015), 923–932.
19. [19] Lambertini, M., Boni, L., Michelotti, A., Gamucci, T., Scotto, T., Gori, S., et al. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA 314:24 (2015), 2632–2640.
20. [20] Leonard, R.C., Adamson, D., Anderson, R., Ballinger, R., Bertelli, G., Coleman, R.E., et al. The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer. J Clin Oncol, 28(Suppl. 15), 2010 abstract 590.
21. [21] Sun, J., Ren, Y., Li, W., Effect of Zoladex administered before chemotherapy on menstruation of patients with breast cancer. China Disability Med 19 (2011), 15–16.
22. [22] Li, J.W., Liu, G.Y., Yu, K.D., Ji, Y.J., Mo, M., Lei, L., et al. Effect of using LHRH analog during chemotherapy (CT) on premature ovarian failure and prognosis in premenopausal patients with early-stage, hormone receptor-positive breast cancer: the primary analysis of a randomized controlled phase III trial. Cancer Res, 75(Suppl. 9), 2015 abstract P1-12-02.
23. [23] Li, M., Huang, H., Liang, Y., Tan, J., Lin, D., Effect of Zoladex administered before chemotherapy on menstruation of patients with breast cancer. Chin J Clin Oncol 35 (2008), 905–907.
24. [24] Del Mastro, L., Lambertini, M., Temporary ovarian suppression with gonadotropin-releasing hormone agonist during chemotherapy for fertility preservation: toward the end of the debate?. Oncol 20:11 (2015), 1233–1235.
25. [25] Coates, A.S., Winer, E.P., Goldhirsch, A., Gelber, R.D., Gnant, M., Piccart-Gebhart, M., et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer 2015. Ann Oncol 26:8 (2015), 1533–1546.
26. [26] National Comprehensive Cancer Network Guidelines – Breast Cancer. Available at: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
27. [27] Lambertini, M., Ceppi, M., Poggio, F., Peccatori, F.A., Azim, H.A. Jr., Ugolini, D., et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol 26:12 (2015), 2408–2419.
28. [28] Pagani, O., Regan, M.M., Walley, B.A., Fleming, G.F., Colleoni, M., Láng, I., et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371:2 (2014), 107–118.
29. [29] Swain, S.M., Jeong, J.-H., Geyer, C.E., Costantino, J.P., Pajon, E.R., Fehrenbacher, L., et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362:22 (2010), 2053–2065.
30. [30] Francis, P.A., Regan, M.M., Fleming, G.F., Láng, I., Ciruelos, E., Bellet, M., et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372:5 (2015), 436–446.